MedPath

Nulibry

These highlights do not include all the information needed to use NULIBRY safely and effectively. See full prescribing information for NULIBRY. NULIBRY (fosdenopterin) for injection, for intravenous useInitial U.S. Approval: 2021

Approved
Approval ID

736aeea3-f206-454d-95d0-fd30964e8aab

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 28, 2022

Manufacturers
FDA

Sentynl Therapeutics, Inc.

DUNS: 078313706

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

fosdenopterin hydrobromide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code42358-295
Application NumberNDA214018
Product Classification
M
Marketing Category
C73594
G
Generic Name
fosdenopterin hydrobromide
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateOctober 28, 2022
FDA Product Classification

INGREDIENTS (6)

mannitolInactive
Quantity: 187.5 mg in 1 1
Code: 3OWL53L36A
Classification: IACT
fosdenopterin hydrobromideActive
Quantity: 9.5 mg in 1 1
Code: X41B5W735T
Classification: ACTIM
sucroseInactive
Quantity: 62.5 mg in 1 1
Code: C151H8M554
Classification: IACT
hydrochloric acidInactive
Code: QTT17582CB
Classification: IACT
ascorbic acidInactive
Quantity: 10 mg in 1 1
Code: PQ6CK8PD0R
Classification: IACT
sodium hydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Nulibry - FDA Drug Approval Details